Overview

The Safety Of Combo Formulation In The Treatment Of Multiple Episodes Of Acute Migraine Over 12 Months

Status:
Completed
Trial end date:
2004-08-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the safety of a single-tablet dose of Combo Formulation for the treatment of moderate to severe migraines
Phase:
Phase 3
Details
Lead Sponsor:
POZEN
Treatments:
Naproxen
Sumatriptan